A Mayo Clinic study published in the Journal of Neuro-Oncology suggests that analyzing DNA in cerebrospinal fluid could ...

Dow Jones biotech giant Amgen stock is trying to break out past a new buy point ahead of the biotech firm's Q3 earnings ...

A Mayo Clinic study published in the Journal of Neuro-Oncology suggests that analyzing DNA in cerebrospinal fluid could provide another source of information when MRI cannot provide a clear brain ...

A prospective cohort study of 837 colorectal cancer patients linked distinct tumor blood-vessel features with colorectal ...

Researchers have identified a previously unrecognized pineal gland tumor type, provisionally named PINNED, defined by a ...

Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") ...

Expert and company perspectives on the role of amivantamab in advancing first-line treatment “Patients with recurrent or metastatic head and neck cancer continue to face a poor prognosis, highlighting ...

Results support continued evaluation of the investigational RYBREVANT FASPRO regimen in the ongoing first-line Phase 3 study Data highlight the role of dual-targeting EGFR and MET, key drivers of ...

Global DNA Methylation Market size is expected to be worth around US$ 6.5 Billion by 2034 from US$ 1.6 Billion in 2024.

Oncology-focused biotech firm BeOne Medicines pops into buy range, boosted by strong demand and stellar earnings growth.

Spread the loveImagine winding back the clock, not on a dusty antique, but on your very own cells. It sounds like something ...

Pancreatic cancer cells are remarkably good at doing one thing: growing. But new Texas A&M research suggests that two tiny molecules already present in the body may help slow them down.